Ignite Creation Date:
2024-05-06 @ 3:08 PM
Last Modification Date:
2024-10-26 @ 1:43 PM
Study NCT ID:
NCT04530643
Status:
COMPLETED
Last Update Posted:
2022-01-28
First Post:
2020-08-25
Brief Title:
A Phase II Study of HY209 Gel for Atopic Dermatitis Patients Shaperon
Sponsor:
Shaperon
Organization:
Shaperon
Study Overview
Official Title:
A Randomized Double-blinded Placebo-controlled Parallel Multi-Center Phase II Clinical Study to Evaluate the Efficacy and Safety of HY209 Gel for Patients With Atopic Dermatitis
Status:
COMPLETED
Status Verified Date:
2022-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Randomized Double-blinded Placebo-controlled Parallel Multi-Center Phase II Clinical Study to Evaluate the Efficacy and Safety of HY209 gel for Patients with Atopic Dermatitis
Detailed Description:
A composition containing G Protein Coupled Receptor 19GPCR19 agonist HY209 and a derivative thereof is found to have a considerable effect in the treatment of atopic dermatitis and is proposed as a pharmaceutical ingredient for prevention treatment and improvement of atopic dermatitis The GPCR19 agonist HY209 is superior to conventional steroid ointment and immunosuppressant ointment in the treatment and improvement of allergic dermatitis It directly reduces the amount of serum immunoglobulin E which is a major factor of allergic dermatitis It increases the T helper type 1TH1 cytokines that alleviate allergic dermatitis pathologies reduces the T helper type 2TH2 cytokines that aggravate allergic dermatitis pathologies and reduces the infiltration of mast cells eosinophils and neutrophils into the dermal cells Thus it can be utilized as a therapeutic drug composition for atopic dermatitis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None